Altimmune's ALT-801 Achieves 5.4% Weight Loss Surpassing Pre-Established Target Of 2%

Altimmune Inc ALT announced results from a prespecified 6-week interim analysis of its Phase 1 trial of ALT-801 in healthy, overweight, and obese volunteers.
The study is currently being conducted in Australia.
The data showed a mean weight loss of 5.4% was achieved by Week 6 with a once-weekly ALT-801 dose of 1.8 mg compared to a weight gain of 0.9% in the placebo group, surpassing the pre-established treatment target of 2% weight loss.
All but one subject who received the 1.8 mg dose achieved at least 3% weight loss.
A lower dose cohort that received a weekly 1.2 mg dose achieved a mean weight loss of 1.8%.
ALT-801 was well-tolerated without dose titration, with transient nausea rates of 14.3% at the 1.2 mg dose and 22.2% at the 1.8 mg dose, and no reports of vomiting, diarrhea, or constipation at either dose.
All nausea events at the 1.8 mg dose were mild in severity.
Results of 12 weeks of dosing are expected to be announced in Q3 2021.
Altimmune will file an additional IND and initiate an obesity program in 2021.
The Company plans to conduct a separate 12-week Phase 1b study in non-alcoholic fatty liver disease (NAFLD) in the U.S., starting in Q3 of 2021.
It will also commence a 52-week biopsy-driven NASH trial in Q1 2022.
The Company will conduct a conference call today at 8:30 am E.T.
Price Action: ALT shares are up 4.74% at $14.8 during the premarket session on the last check Wednesday.